{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:11:14Z","timestamp":1792725074625,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,16]]},"DOI":"10.7759\/cureus.58416","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:43:45Z","timestamp":1713282225000},"source":"Crossref","is-referenced-by-count":26,"title":["A Review of Recent Advances in the Management of Alzheimer\u2019s Disease"],"prefix":"10.7759","author":[{"given":"Skylynn","family":"Thangwaritorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Metchikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidushi","family":"Razdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suliman","family":"Ghafary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nic.2005.09.009","article-title":"Pathophysiology of Alzheimer's disease","volume":"15","author":"Imbimbo BP","year":"2005","unstructured":"Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin N Am. 2005, 15:727-53. 10.1016\/j.nic.2005.09.009","journal-title":"Neuroimaging Clin N Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2016.06.014","article-title":"Insights on the pathophysiology of Alzheimer's disease: the crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system","volume":"68","author":"D\u00e1 Mesquita S","year":"2016","unstructured":"D\u00e1 Mesquita S, Ferreira AC, Sousa JC, Correia-Neves M, Sousa N, Marques F. Insights on the pathophysiology of Alzheimer's disease: the crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neurosci Biobehav Rev. 2016, 68:547-62. 10.1016\/j.neubiorev.2016.06.014","journal-title":"Neurosci Biobehav Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2010.01.002","article-title":"Epigenetic regulation in the pathophysiology of Alzheimer's disease","volume":"90","author":"Chouliaras L","year":"2010","unstructured":"Chouliaras L, Rutten BP, Kenis G, et al.. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol. 2010, 90:498-510. 10.1016\/j.pneurobio.2010.01.002","journal-title":"Prog Neurobiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston G","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, et al.. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020, 396:413-46. 10.1016\/S0140-6736(20)30367-6","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30412-9","article-title":"APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches","volume":"20","author":"Serrano-Pozo A","year":"2021","unstructured":"Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021, 20:68-80. 10.1016\/S1474-4422(20)30412-9","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90355-j","article-title":"The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization","volume":"56","author":"Orrego F","year":"1993","unstructured":"Orrego F, Villanueva S. The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience. 1993, 56:539-55. 10.1016\/0306-4522(93)90355-j","journal-title":"Neuroscience"},{"key":"ref7","article-title":"Cholinesterase Inhibitors","author":"Singh R","year":"2024","unstructured":"Singh R, Sadiq NM. Cholinesterase Inhibitors. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3741","article-title":"Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study","volume":"24","author":"Kr\u00f6ger E","year":"2015","unstructured":"Kr\u00f6ger E, Van Marum R, Souverein P, Carmichael PH, Egberts T. Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiol Drug Saf. 2015, 24:276-85. 10.1002\/pds.3741","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12184","article-title":"Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non-hypertensive Alzheimer's patients","volume":"7","author":"Al-Hamed FS","year":"2021","unstructured":"Al-Hamed FS, Kouniaris S, Tamimi I, et al.. Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non-hypertensive Alzheimer's patients. Alzheimers Dement (N Y). 2021, 7:e12184. 10.1002\/trc2.12184","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107134","article-title":"Efficacy and safety of donepezil for mild cognitive impairment: a systematic review and meta-analysis","volume":"213","author":"Zhang X","year":"2022","unstructured":"Zhang X, Lian S, Zhang Y, Zhao Q. Efficacy and safety of donepezil for mild cognitive impairment: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2022, 213:107134. 10.1016\/j.clineuro.2022.107134","journal-title":"Clin Neurol Neurosurg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000080972","article-title":"A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease","volume":"19","author":"Karaman Y","year":"2005","unstructured":"Karaman Y, Erdo\u011fan F, K\u00f6seo\u011flu E, Turan T, Ersoy AO. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005, 19:51-6. 10.1159\/000080972","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref12","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Hansen RA","year":"2008","unstructured":"Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008, 3:211-25.","journal-title":"Clin Interv Aging"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000008243","article-title":"A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease","volume":"44","author":"Farlow M","year":"2000","unstructured":"Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000, 44:236-41. 10.1159\/000008243","journal-title":"Eur Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2011.7.3.137","article-title":"Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease","volume":"7","author":"Han HJ","year":"2011","unstructured":"Han HJ, Lee JJ, Park SA, et al.. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011, 7:137-42. 10.3988\/jcn.2011.7.3.137","journal-title":"J Clin Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.1.9","article-title":"Galantamine in Alzheimer's disease","volume":"8","author":"Razay G","year":"2008","unstructured":"Razay G, Wilcock GK. Galantamine in Alzheimer's disease. Expert Rev Neurother. 2008, 8:9-17. 10.1586\/14737175.8.1.9","journal-title":"Expert Rev Neurother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12195","article-title":"Galantamine treatment in outpatients with mild Alzheimer's disease","volume":"129","author":"Richarz U","year":"2014","unstructured":"Richarz U, Gaudig M, Rettig K, Schauble B. Galantamine treatment in outpatients with mild Alzheimer's disease. Acta Neurol Scand. 2014, 129:382-92. 10.1111\/ane.12195","journal-title":"Acta Neurol Scand"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group","volume":"321","author":"Wilcock GK","year":"2000","unstructured":"Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000, 321:1445-9. 10.1136\/bmj.321.7274.1445","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg B","year":"2003","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, Schmitt F, Ferris S, M\u00f6bius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003, 348:1333-41. 10.1056\/NEJMoa013128","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.10.005","article-title":"Pharmacokinetic study of memantine in healthy and renally impaired subjects","volume":"79","author":"Periclou A","year":"2006","unstructured":"Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006, 79:134-43. 10.1016\/j.clpt.2005.10.005","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein S","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al.. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022, 9:197-210. 10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck CH","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al.. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023, 388:9-21. 10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims JR","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al.. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023, 330:512-27. 10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin S","year":"2022","unstructured":"Shcherbinin S, Evans CD, Lu M, et al.. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022, 79:1015-24. 10.1001\/jamaneurol.2022.2793","journal-title":"JAMA Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng E","year":"2022","unstructured":"Teng E, Manser PT, Pickthorn K, et al.. Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022, 79:758-67. 10.1001\/jamaneurol.2022.1375","journal-title":"JAMA Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207663","article-title":"Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet","volume":"101","author":"Monteiro C","year":"2023","unstructured":"Monteiro C, Toth B, Brunstein F, et al.. Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet. Neurology. 2023, 101:e1391-401. 10.1212\/WNL.0000000000207663","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease","volume":"44","author":"Wischik CM","year":"2015","unstructured":"Wischik CM, Staff RT, Wischik DJ, et al.. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis. 2015, 44:705-20. 10.3233\/JAD-142874","journal-title":"J Alzheimers Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(Hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock GK","year":"2018","unstructured":"Wilcock GK, Gauthier S, Frisoni GB, et al.. Potential of low dose leuco-methylthioninium bis(Hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: cohort analysis as modified primary outcome in a phase III clinical trial. J Alzheimers Dis. 2018, 61:435-57. 10.3233\/JAD-170560","journal-title":"J Alzheimers Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2017.26","article-title":"Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer's disease suggest disease modification potential","volume":"4","author":"Abushakra S","year":"2017","unstructured":"Abushakra S, Porsteinsson A, Scheltens P, et al.. Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer's disease suggest disease modification potential. J Prev Alzheimers Dis. 2017, 4:149-56. 10.14283\/jpad.2017.26","journal-title":"J Prev Alzheimers Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2021-0022","article-title":"NM101 phase III study of NE3107 in Alzheimer's disease: rationale, design\u00a0and therapeutic modulation of neuroinflammation and insulin resistance","volume":"11","author":"Reading CL","year":"2021","unstructured":"Reading CL, Ahlem CN, Murphy MF. NM101 phase III study of NE3107 in Alzheimer's disease: rationale, design\u00a0and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener Dis Manag. 2021, 11:289-98. 10.2217\/nmt-2021-0022","journal-title":"Neurodegener Dis Manag"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05743-0","article-title":"Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study","volume":"65","author":"Zheng J","year":"2022","unstructured":"Zheng J, Xu M, Walker V, et al.. Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study. Diabetologia. 2022, 65:1664-75. 10.1007\/s00125-022-05743-0","journal-title":"Diabetologia"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00795-7","article-title":"A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia","volume":"13","author":"Xiao S","year":"2021","unstructured":"Xiao S, Chan P, Wang T, et al.. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. Alzheimers Res Ther. 2021, 13:62. 10.1186\/s13195-021-00795-7","journal-title":"Alzheimers Res Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003904","article-title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease","volume":"88","author":"Relkin NR","year":"2017","unstructured":"Relkin NR, Thomas RG, Rissman RA, et al.. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017, 88:1768-75. 10.1212\/WNL.0000000000003904","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01169-x","article-title":"Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial","volume":"15","author":"Dubois B","year":"2023","unstructured":"Dubois B, L\u00f3pez-Arrieta J, Lipschitz S, et al.. Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res Ther. 2023, 15:39. 10.1186\/s13195-023-01169-x","journal-title":"Alzheimers Res Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab452","article-title":"A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment","volume":"145","author":"Levey AI","year":"2022","unstructured":"Levey AI, Qiu D, Zhao L, et al.. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain. 2022, 145:1924-38. 10.1093\/brain\/awab452","journal-title":"Brain"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00263-5","article-title":"Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"20","author":"Kehoe PG","year":"2021","unstructured":"Kehoe PG, Turner N, Howden B, et al.. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2021, 20:895-906. 10.1016\/S1474-4422(21)00263-5","journal-title":"Lancet Neurol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01097-2","article-title":"Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial","volume":"14","author":"Vi\u00f1a J","year":"2022","unstructured":"Vi\u00f1a J, Escudero J, Baquero M, et al.. Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial. Alzheimers Res Ther. 2022, 14:164. 10.1186\/s13195-022-01097-2","journal-title":"Alzheimers Res Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00271-2","article-title":"Neuroprotective effect of trans-resveratrol in mild to moderate Alzheimer disease: a randomized, double-blind trial","volume":"10","author":"Gu J","year":"2021","unstructured":"Gu J, Li Z, Chen H, Xu X, Li Y, Gui Y. Neuroprotective effect of trans-resveratrol in mild to moderate Alzheimer disease: a randomized, double-blind trial. Neurol Ther. 2021, 10:905-17. 10.1007\/s40120-021-00271-2","journal-title":"Neurol Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200896","article-title":"Benfotiamine and cognitive decline in Alzheimer's disease: results of a randomized placebo-controlled phase iIa clinical trial","volume":"78","author":"Gibson GE","year":"2020","unstructured":"Gibson GE, Luchsinger JA, Cirio R, et al.. Benfotiamine and cognitive decline in Alzheimer's disease: results of a randomized placebo-controlled phase iIa clinical trial. J Alzheimers Dis. 2020, 78:989-1010. 10.3233\/JAD-200896","journal-title":"J Alzheimers Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa332","article-title":"BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain","volume":"143","author":"Sur C","year":"2020","unstructured":"Sur C, Kost J, Scott D, et al.. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. Brain. 2020, 143:3816-26. 10.1093\/brain\/awaa332","journal-title":"Brain"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00797-x","article-title":"First-in-human randomized trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of the KDM1A inhibitor vafidemstat","volume":"35","author":"Antonijoan RM","year":"2021","unstructured":"Antonijoan RM, Ferrero-Cafiero JM, Coimbra J, et al.. First-in-human randomized trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of the KDM1A inhibitor vafidemstat. CNS Drugs. 2021, 35:331-44. 10.1007\/s40263-021-00797-x","journal-title":"CNS Drugs"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00336-2","article-title":"Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial","volume":"12","author":"Yulug B","year":"2023","unstructured":"Yulug B, Altay O, Li X, et al.. Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Transl Neurodegener. 2023, 12:4. 10.1186\/s40035-023-00336-2","journal-title":"Transl Neurodegener"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01151-z","article-title":"CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease","volume":"14","author":"Lerner AJ","year":"2022","unstructured":"Lerner AJ, Arnold SE, Maxfield E, et al.. CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease. Alzheimers Res Ther. 2022, 14:198. 10.1186\/s13195-022-01151-z","journal-title":"Alzheimers Res Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-051343","article-title":"Repurposing bromocriptine for A\u03b2 metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations","volume":"11","author":"Kondo T","year":"2021","unstructured":"Kondo T, Banno H, Okunomiya T, et al.. Repurposing bromocriptine for A\u03b2 metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. BMJ Open. 2021, 11:e051343. 10.1136\/bmjopen-2021-051343","journal-title":"BMJ Open"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg GT","year":"2020","unstructured":"Grossberg GT, Kohegyi E, Mergel V, et al.. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020, 28:383-400. 10.1016\/j.jagp.2019.09.009","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial","volume":"16","author":"Herring WJ","year":"2020","unstructured":"Herring WJ, Ceesay P, Snyder E, et al.. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020, 16:541-51. 10.1002\/alz.12035","journal-title":"Alzheimers Dement"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110887","article-title":"Melatonin regulates A\u03b2 production\/clearance balance and A\u03b2 neurotoxicity: a potential therapeutic molecule for Alzheimer's disease","volume":"132","author":"Li Y","year":"2020","unstructured":"Li Y, Zhang J, Wan J, Liu A, Sun J. Melatonin regulates A\u03b2 production\/clearance balance and A\u03b2 neurotoxicity: a potential therapeutic molecule for Alzheimer's disease. Biomed Pharmacother. 2020, 132:110887. 10.1016\/j.biopha.2020.110887","journal-title":"Biomed Pharmacother"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020461","article-title":"Eicosapentaenoic acid is associated with decreased incidence of Alzheimer's dementia in the oldest old","volume":"13","author":"Melo van Lent D","year":"2021","unstructured":"Melo van Lent D, Egert S, Wolfsgruber S, et al.. Eicosapentaenoic acid is associated with decreased incidence of Alzheimer's dementia in the oldest old. Nutrients. 2021, 13:461. 10.3390\/nu13020461","journal-title":"Nutrients"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291x(92)90837-b","article-title":"Vitamin E protects nerve cells from amyloid beta protein toxicity","volume":"186","author":"Behl C","year":"1992","unstructured":"Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun. 1992, 186:944-50. 10.1016\/0006-291x(92)90837-b","journal-title":"Biochem Biophys Res Commun"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361704","article-title":"A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study","volume":"336","author":"Sano M","year":"1997","unstructured":"Sano M, Ernesto C, Thomas RG, et al.. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N Engl J Med. 1997, 336:1216-22. 10.1056\/NEJM199704243361704","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282834","article-title":"Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial","volume":"311","author":"Dysken MW","year":"2014","unstructured":"Dysken MW, Sano M, Asthana S, et al.. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014, 311:33-44. 10.1001\/jama.2013.282834","journal-title":"JAMA"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S95362","article-title":"Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study","volume":"11","author":"Ohnuma T","year":"2016","unstructured":"Ohnuma T, Toda A, Kimoto A, et al.. Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study. Clin Interv Aging. 2016, 11:29-36. 10.2147\/CIA.S95362","journal-title":"Clin Interv Aging"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-6-31","article-title":"Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"6","author":"Henderson ST","year":"2009","unstructured":"Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009, 6:31. 10.1186\/1743-7075-6-31","journal-title":"Nutr Metab (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/219507-a-review-of-recent-advances-in-the-management-of-alzheimers-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:43:52Z","timestamp":1713282232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/219507-a-review-of-recent-advances-in-the-management-of-alzheimers-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":52,"URL":"https:\/\/doi.org\/10.7759\/cureus.58416","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}